Summit Financial LLC Purchases 17,528 Shares of Merck & Co., Inc. $MRK

Summit Financial LLC increased its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 14.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 137,745 shares of the company's stock after acquiring an additional 17,528 shares during the period. Summit Financial LLC's holdings in Merck & Co., Inc. were worth $14,615,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the company. Howland Capital Management LLC increased its stake in Merck & Co., Inc. by 0.8% in the fourth quarter. Howland Capital Management LLC now owns 46,672 shares of the company's stock valued at $4,952,000 after acquiring an additional 371 shares during the last quarter. Circle Wealth Management LLC increased its stake in Merck & Co., Inc. by 11.8% in the fourth quarter. Circle Wealth Management LLC now owns 181,376 shares of the company's stock valued at $19,092,000 after acquiring an additional 19,145 shares during the last quarter. Quadrant Capital Group LLC boosted its holdings in shares of Merck & Co., Inc. by 1.1% in the 4th quarter. Quadrant Capital Group LLC now owns 87,645 shares of the company's stock valued at $9,226,000 after purchasing an additional 991 shares in the last quarter. Livet Wealth LLC bought a new position in shares of Merck & Co., Inc. in the 4th quarter valued at $202,000. Finally, Advisors Asset Management Inc. increased its stake in shares of Merck & Co., Inc. by 0.7% in the 4th quarter. Advisors Asset Management Inc. now owns 342,689 shares of the company's stock valued at $36,071,000 after purchasing an additional 2,380 shares during the last quarter. 76.07% of the stock is owned by institutional investors.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck Animal Health announced a definitive agreement to acquire TARGAN, a poultry biodevice company, which could strengthen Merck’s animal health division and broaden its technology-driven growth opportunities. Merck Animal Health to Acquire TARGAN
• Positive Sentiment: Merck saw unusually heavy call option buying, with traders purchasing 170,441 calls, a sharp jump versus normal volume that often signals bullish expectations from sophisticated investors.
• Positive Sentiment: Wells Fargo reiterated a buy rating on Merck, while another article highlighted that Wall Street’s overall bullish view continues to keep MRK on investors’ radar.
• Neutral Sentiment: Merck has also been featured in broader market commentary and “most searched” lists, suggesting rising attention rather than a new fundamental catalyst.
• Neutral Sentiment: One article noted Merck’s recent trading uptick but said it lagged the broader market, indicating modest price strength rather than a major breakout. Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on MRK shares. Deutsche Bank Aktiengesellschaft raised Merck & Co., Inc. from a "hold" rating to a "buy" rating and set a $150.00 price target for the company in a report on Friday, February 13th. Weiss Ratings cut Merck & Co., Inc. from a "hold (c+)" rating to a "hold (c)" rating in a research report on Friday, May 15th. Citigroup initiated coverage on Merck & Co., Inc. in a research note on Wednesday, May 6th. They set a "neutral" rating and a $125.00 target price for the company. JPMorgan Chase & Co. increased their target price on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an "overweight" rating in a report on Monday, April 6th. Finally, Barclays assumed coverage on shares of Merck & Co., Inc. in a research note on Friday, February 20th. They issued an "overweight" rating and a $140.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $128.18.

Merck & Co., Inc. Stock Down 1.4%

Shares of NYSE:MRK opened at $119.05 on Friday. The company has a fifty day moving average of $116.55 and a 200-day moving average of $113.23. The company has a market capitalization of $294.04 billion, a PE ratio of 33.54, a price-to-earnings-growth ratio of 2.72 and a beta of 0.21. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. Merck & Co., Inc. has a 52-week low of $76.66 and a 52-week high of $125.14.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating analysts' consensus estimates of ($1.47) by $0.19. The company had revenue of $16.29 billion during the quarter, compared to analysts' expectations of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.Merck & Co., Inc.'s revenue was up 4.9% compared to the same quarter last year. During the same period in the prior year, the company earned $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, equities analysts predict that Merck & Co., Inc. will post 5.17 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 8th. Shareholders of record on Monday, June 15th will be given a $0.85 dividend. The ex-dividend date is Monday, June 15th. This represents a $3.40 annualized dividend and a yield of 2.9%. Merck & Co., Inc.'s dividend payout ratio (DPR) is currently 95.77%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.